Cutaneous mucormycosis

SKINmed

Volumn 11, Issue 3, 2013, Pages 155-160

  Skiada, Anna ^a   Petrikkos, George ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

DEBRIDEMENT; DERMATOMYCOSIS; HUMAN; METHODOLOGY; MUCORMYCOSIS; REVIEW; RISK FACTOR;

ANTIFUNGAL AGENTS; DEBRIDEMENT; DERMATOMYCOSES; HUMANS; MUCORMYCOSIS; RISK FACTORS;

EID: 84882955289     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Sun H-Y, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11:301–311
2. Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res. 2007;111:509–547.
3. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10(suppl 1):31–47.
4. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265–273.
5. Roden M, Zaoutis T, Buchanan W, et al. Epidemiology and outcome of zygomycosis: a report of 929 reported cases. Clin Infect Dis. 2005;41:634–653.
6. Skiada A, Pagano L, Groll A, et al; for the European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe. Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–1867.
7. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of Zygomycosis (mucormycosis), France, 1997- 2006. Emerg Infect Dis. 2009;15:1395–1401.
8. Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive Mucormycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335–342.
9. Saegeman V, Maertens J, Meersseman W, et al. Increasing incidence of mucormycosis in university hospital, Belgium. Emerg Infect Dis. 2010;16:1456–1458.
10. Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect. 2009;suppl 5:41–45.
11. Xue-lian Lu, Ze-hu Liu, Yong-nian Shen, et al. Primary cutaneous zygomycosis caused by Rhizomucor variabilis: a new endemic zygomycosis? A case report and review of 6 cases reported from China. Clin Infect Dis. 2009;49:e39–e43.
12. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24:411–445.
13. Cooter RD, Lim IS, Ellis DH, Leitch IOW. Burn wound zygomycosis caused by Apophysomyces elegans. J Clin Microbiol. 1990;28:2151–2153.
14. Blair JE, Fredrikson LJ, Pockaj BA, Lucaire CS. Locally invasive cutaneous Apophysomyces elegans infection acquired from snapdragon patch test. Mayo Clin Proc. 2002;77:717–720.
15. Tanphaichitr VS, Chaiprasert A, Suvatte V, Thasnakorn P. Subcutaneous mucormycosis caused Saksenaea vasiformisin a thalassaemic child: first case report in Thailand. Mycoses. 1990;6:303–309.
16. Bearer EA, Nelson PA, Chowers M, Davis CE. Cutaneous zygomycosiscaused by Saksenaea vasiformis in a diabetic patient. J Clin Microbiol. 1994;32:1823–1824.
17. Al-Hedaithy M. Cutaneous zygomycosis due to Saksenaea vasiformis: Case report and literature review. Ann Saudi Med. 1998;18:428–431.
18. Burrell SR, Ostlie DJ, Saubolle M, Dimler M, Barbour SD. Apophysomyces elegans infection associated with cactusspine injury in an immunocompetent pediatric patient. Pediatr Infect Dis J. 1998;17:663–664.
19. Saravia-Flores M, Guaran DM, Argueta V. Invasive cutaneous infection caused by Apophysomyces elegans associated with a spider bite. Mycoses. 2009;53:259–261.
20. Lechevalier P, Hermoso DG, Carol A, et al. Molecular diagnosis of Saksenaea vasiformis cutaneous infection after scorpion sting in an immunocompetent adolescent. J Clin Microbiol. 2008;3169–3172.
21. Adam RD, Hunter G, DiTomasso J, Comerci G, Jr.. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis. 1994;19:67–76.
22. Chambers CJ, Merin MR, Fung MA, Huntley A, Sharon VR. Primary cutaneous mucormycosis at sites of insulin injection. J Am Acad Dermatol. 2011;64:e79–e80.
23. Andresen D, Donaldson A, Choo L, et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet. 2005;365:876–878.
24. Patino JF, Castro D, Valencia A, Morales P. Necrotizing soft tissue lesions after a volcanic cataclysm. World J Surg. 1991;15:240–247.
25. Zachary D, Chapin K, Binns L, Tashima K. Cutaneous mucormycosis complicating a polymicrobial wound infection following a dog bite. Case Rep Infect Dis. 2011;2011:348046.
26. Petrikkos GL, Skiada A, Sambatakou H, et al. Mucormycosis: ten-year experience in a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis. 2003;22:753–756.
27. Ayala-Gaytan JJ, Petersen-Morfin S, Guajardo-Lara CE, et al. Cutaneous zygomycosis in immunocompetent patients in Mexico. Mycoses. 2010;53:538–540.
28. Arnaiz-Garcia ME, Alonso-Pena D, del Carmen Gonzalez- Vela M, et al. Cutaneous mucormycosis: report of five cases and review of the literature. J Plast Reconstr Aesthet Surg. 2009;62:e434–e441.
29. Lewis RE. Cutaneous mucormycosis in tornado survivors. Curr Fungal Infect Rep. 2011;5:187–189.
30. Ledgard JP, Sebastiaan van Hal, Greenwood JE. Primary cutaneous zygomycosis in a burns patient: a review. J Burn Care Res. 2008;29:286–290.
31. Chander J, Kaur J, Attri A, Mohan H. Primary cutaneous zygomycosis from a tertiary care centre in north-west India. Indian J Med Res. 2010;3:765–770.
32. Salati SA, Rabah SM. Cutaneous mucormycosis in a leukemic patient. J Coll Physicians Surg Pak. 2011;21:109–110.
33. Sankar J, Arun S, Sankar MJ, et al. Primary cutaneous mucormycosis during induction chemotherapy in a child with acute lymphoblastic leukemia. Indian J Pediatr. 2009;76:1161–1163.
34. Lumbang WA, Caufield BA. Vesicular eruption on the arm of an infant. Dermatol Online J. 2010;16:13.
35. Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect. 2009;15 (suppl 5):55–59.
36. Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Reviews. 2005;18:556–569.
37. Chakrabarti A, Chatterjee SS, Das A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009;85:573–581.
38. Chakrabarti A. Cutaneous zygomycosis: major concerns. Indian J Med Res. 2010;131:739–741.
39. Song KR, Wong MS, Yeung C. Primary cutaneous zygomycosis in an immunodeficient infant. A case report and review of the literature. Ann Plast Surg. 2008;60:433–436.
40. Kerr OA, Bong C, Wallis C, Tidman MJ. Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br J Dermatol. 2004;150:1212–1234.
41. Clauss H, Samuel R. Simultaneous mold infections in an orthotopic heart transplant recipient. Transpl Infect Dis. 2008;10:343–345.
42. Oliveira-Neto MP, Da Silva M, Monteiro PC, et al. Cutaneous mucormycosis in a young, immunocompetent girl. Med Mycol. 2006;44:567–570.
43. Hansen JP, Kristiansson AK, Stone MS. A neutropenic child with a purple lesion of the thigh. Pediatr Dermatol. 2007;24:560–561.
44. Rubin AI, Grossman ME. Bull’s-eye cutaneous infarct of zygomycosis: a bedside diagnosis confirmed by touch preparation. J Am Acad Dermatol. 2004;51:996–1001.
45. Zhao Y, Zhang Q, Li L, et al. Primary cutaneous mucormycosis caused by Rhizomucor variabilis in an immunocompromised patient. Mycopathologia. 2009;168:243–247.
46. Tomita H, Muroi E, Takenaka M, et al. Rhizomucor variabilis infection in human cutaneous mucormycosis. Clin Experiment Dermatol. 2010;36:305–317.
47. Hemashettar BM, Patil RN, O’Donnell K, et al. Chronic rhinofacial mucormycosis caused by Mucor irregularis (Rhizomucor variabilis) in India. J Clin Microbiol. 2011;49:2372–2375.
48. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations and management. Infect Dis Clin N Am. 2006;20:581–607.
49. Dannaoui E. Molecular tools for identification of Zygomycetes and the diagnosis of zygomycosis. Clin Microbiol Infect. 2009;15(suppl 5):66–70.
50. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis. 2007;44:1078–1083.
51. Moran SL, Strickland J, Shin AY. Upper-extremity mucormycosis infections in immunocompetent patients. J Hand Surgery. 2006;31A:1201–1205.
52. Shafer MR. Use of hyperbaric oxygen as adjunct therapy to surgical debridement of complicated wounds. Semin Perioper Nurs. 1993;2:256–262.
53. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferon-gamma and granulocyte-macrophage colonystimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191:1180–1187.